Use this URL to cite or link to this record in EThOS: http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.491390
Title: Human ether-a-go-go related gene (hERG) potassium channel gating and drug block
Author: Dalibalta, Sarah
ISNI:       0000 0001 3402 5896
Awarding Body: University of Leicester
Current Institution: University of Leicester
Date of Award: 2008
Availability of Full Text:
Access from EThOS:
Access from Institution:
Abstract:
hERG encodes the a-subunit of the rapid delayed rectifier potassium current, a crucial current for normal repolarisation of the cardiac action potential. Pharmacological block of hERG is associated with arrhythmias and sudden death. Given its physiological importance, aspects of both the gating and pharmacology of this channel were investigated.;hERG has unusual gating properties characterised by slow activation and deactivation gating. The roles of conserved S6 glycines (Gly648 and Gly657) in hERG as hinges for activation gating were studied. Glycine residues impart flexibility that is thought to be conducive for channel opening. However, mutations at positions 648 and 657 altered gating in a manner consistent with a role in protein packing rather than flexibility. Deactivation gating in hERG is slow due to interactions between the amino-terminus, the voltage sensor, and the pore that stabilise the open state. The pore mutation V659A dramatically slowed channel deactivation and reduced drug block. Replacing Val659 with larger hydrophobic residues resulted in faster deactivation kinetics, but in contrast, V659G hERG was constitutively open. It was concluded that Val659 mutations influence deactivation through hydrophobic interactions with the S4-S5 linker that couples S6 to the voltage sensor. Effects on drug binding correlated with deactivation rates, indicating that Val659 mutations have allosteric rather than direct effects on drug binding.;Tyr652 is thought to be a critical residue for high affinity drug binding. However, this study showed that the contribution of Tyr652 to drug binding varied considerably among 24 compounds tested, with the majority of low affinity blockers being relatively insensitive to the Y652A mutation. Pharmacophore models generated from the results suggest that higher affinity compounds are longer than lower affinity compounds and simultaneously interact with multiple inner cavity residues. The compact structure of low affinity, Y652A-insensitive drugs permits multiple binding modes, making the compounds less reliant on interactions with Tyr652.
Supervisor: Not available Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.491390  DOI: Not available
Share: